| Literature DB >> 35990015 |
Nadja N V Mayrink1,2, Luís Alcoforado1,3, Arthur Chioro4, Felipe Fernandes2, Thaisa S Lima5, Erika B Camargo6, Ricardo A M Valentim2.
Abstract
Introduction: The current debate on the process of technological innovation points out as a challenge for universities consolidation of competencies that allow the generation and transfer of knowledge to society. The Translational Research (TR) approach has as one of its main objectives the acceleration of the innovation process, based on the transposition from basic science to applied science and innovation, which comprises the different stages of research, development and innovation. The literature points out that the dynamics of translation, which results in new technologies, are complex, transdisciplinary, inter-institutional, systemic, and non-linear. The main objective of this review is to contribute to the adoption of institutional strategies and the formulation of public policies aimed at solving today's social and economic challenges, ensuring access to technologies and sustainability for the health system. The specific objectives were: (i) to systematize studies that characterized translational research in medical devices; (ii) map the challenges for the implementation of translational health research; (iii) contribute to the design of institutional strategies; and (iv) support the formulation of public policies.Entities:
Keywords: health innovation; health technologies; medical device; medical research; translational research
Year: 2022 PMID: 35990015 PMCID: PMC9385029 DOI: 10.3389/fdgth.2022.957367
Source DB: PubMed Journal: Front Digit Health ISSN: 2673-253X
Figure 1PRISMA-Scr flowchart.
Figure 2Classification of the included articles, by object of study.
Incidence of themes related to the attributes of translational research grouped by the Institutional dimension.
| Dimension: Knowledge | Incidence |
|---|---|
| Regulatory technical (technical standards) | 28 (85%) |
| Health regulatory (safety and efficacy) | 27 (82%) |
| Knowledge about designing and conducting in vitro and in vivo assays | 25 (75%) |
| Health Economics | 22 (66%) |
| Regulatory Ethics | 20 (60%) |
| Intellectual protection and asset management | 21 (63%) |
| Knowledge of the conceptual model of the disease, problem area, workflow or process | 18 (54%) |
| Product Life Cycle | 16 (48%) |
| Product design | 12 (36%) |
Note: Articles grouped by barrier and dimensions according to incidence are available in .
Incidence of themes related to the attributes of translational research grouped by the Institutional dimension.
| Dimension: Institutional or inter-institutional structure | Incidence |
|---|---|
| Interdisciplinary and Transdisciplinary Teams | 31 (94%) |
| Collaborative or networked action linking multiple researchers and research centers and the government | 28 (85%) |
| Development of partnerships with industry | 21 (64%) |
| Education and Training on pertinent topics and with appropriate educational resources | 22 (66%) |
| Support to researchers in project management, monitoring and evaluation | 20 (60%) |
| Support about available funding (Governmental agencies and non-governmental entities) | 18 (54%) |
| Strategic and risk management support | 15 (45%) |
| Administrative, legal and/or regulatory support | 14 (42%) |
| Prototyping in industrial design based on clinical and user needs assessment | 14 (42%) |
| Proof of concept, prototype and in vitro testing capabilities | 13 (39%) |
| Mentoring and supervision | 11 (33%) |
| Adoption of business and marketing strategies | 11 (33%) |
| Opportunity for start-up creation, technology transfer or licensing | 10 (30%) |
| Adoption of good laboratory practices (GLP) and quality management | 7 (21%) |
| In-house or collaborative clinical research infrastructure | 6 (18%) |
| Engaging institutional leaders to remove technical and administrative barriers | 6 (18%) |
Note: Articles grouped by barrier and dimensions according to incidence are available in .
Incidence of the barriers pointed out as determinants to be faced by academic laboratories in the implementation of translational research, from the analysis dimension.
| Barriers | Dimension | Incidence | ||
|---|---|---|---|---|
| Kno | Cap | IS | ||
| Untrained staff |
|
| 24 (73%) | |
| Lack of institutional support for the teams |
| 21 (64%) | ||
| Inadequate financing |
| 20 (60%) | ||
| Institutional model and public policies based on disciplines and linear innovation process |
| 19 (57%) | ||
| Difficulty in interacting with industry and society |
|
| 18 (54%) | |
| Difficulty in communication |
|
| 16 (48%) | |
| Researcher Training Programs |
|
| 15 (45%) | |
| High cost of the research translation process and patent maintenance |
| 11 (33%) | ||
| Long time to complete the entire translation process |
|
|
| 12 (36%) |
| Industry disinterest |
| 5 (15%) | ||
| Lack of agility in the university’s administrative processes |
| 3 (9%) | ||
Abbreviations: Kno, knowledge; Cap, capacity; IS, institutional structure.
Note: Articles grouped by barrier and dimensions according to incidence are available in .
Incidence of themes related to the attributes of translational research grouped by the capacity dimension.
| Dimension: Capacity | Incidence |
|---|---|
| Collaborative Efforts | 31 (94%) |
| Attention to unmet clinical needs | 23 (70%) |
| Assessment of the technical, clinical and economic feasibility of the innovation | 22 (69%) |
| Identification of promising technologies, at the frontier of knowledge and/or more cost effective | 19 (58%) |
| Generation of value in healthcare | 19 (58%) |
| Assessment of the technology’s market potential and business plan | 21 (64%) |
| Effective communication with different stakeholders | 19 (58%) |
| Tolerance to error and risk | 15 (45%) |
| Use of project management tools and methodologies and management support | 14 (42%) |
| Analysis of the technology’s framework in the risk class to identify technical and sanitary regulations and requirements | 14 (42%) |
| Innovation project documentation containing milestones, timeline, requirements, and available resources | 10 (30%) |
| Attention to product usability in the early stages, in order to increase the chances of success and allow for timely reorientation in development | 9 (27%) |
| Entrepreneurship | 4 (12%) |
| Creativity | 4 (12%) |
Note: Articles grouped by barrier and dimensions according to incidence are available in .
Incidence of factors indicated as determinants for favoring the implementation of translational research, from the dimension of analysis.
| Factors | Dimension | Incidence | ||
|---|---|---|---|---|
| Kno | Cap | IS | ||
| Multidisciplinary, collaborative, and networked teamwork |
|
| 31 (94%) | |
| Team skilled in technical and regulatory requirements |
| 28 (85%) | ||
| Cooperation with the industry |
|
| 24 (73%) | |
| Qualified and effective communication between the actors involved |
|
| 21 (64%) | |
| Valuing the patient’s and technology user’s perspective |
|
| 19 (57%) | |
| Clinical immersion to identify and assess unmet clinical problems and needs |
|
| 14 (46%) | |
| Offering regular funding to maintain the team |
| 14 (46%) | ||
| Changing the paradigm of researcher training |
| 14 (46%) | ||
| Selection of Projects with high translation potential |
|
| 14 (46%) | |
| Project Management |
|
| 14 (46%) | |
| Alignment of innovation with institutional and local priorities |
| 10 (30%) | ||
| Transparency with the aim of improving the quality of research and avoiding duplication of effort |
| 5 (15%) | ||
| Sustainability (effective technologies developed for low-resource environments) |
|
|
| 4 (12%) |
Abbreviations: Kno, knowledge; Cap, capacity; IS, institutional structure.
Note: Articles grouped by barrier and dimensions according to incidence are available in .